Citations

Clear

3 citation(s) found for "Schalper, KA".

AI-derived CD8⁺ cytotoxic T-cell immune signatures from baseline H&E images to predict immunotherapy benefit over chemotherapy in non–small cell lung cancer: Blinded validation in CheckMate-227 (CM227).
Barrera, Cristian , Safta, Wiem, Mutha, Pushkar, Grootendorst, Diederik J., Mustatea, Oana, Eddy, Nathanial, Pathak, Tilak, Gregorio, Miguel Lopez de Rodas, Schalper, Kurt A , Ramalingam, Suresh S., Velcheti, Vamsidhar, Madabhushi, Anant, Mutha, Pushkar , Khorrami, Mohammadhadi , Grootendorst, Diederik J., Eddy, Nathanial R., Rodas, Miguel López de , Ramalingam, Suresh S. , Madabhushi, Anant

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8534-8534

10.1200/jco.2026.44.16_suppl.8534 Get It

8534 Background: Immunotherapy (IO) has transformed treatment for non–small cell lung cancer (NSCLC), but not all patients (pts) benefit, underscoring the need for predictive biomarkers to guide IO versus chemotherapy (Ch). CheckMate 227 (CM227; NCT02477826) showed a survival benefit of first-line nivolumab plus ipilimumab (nivo+ipi) over Ch in stage IV NSCLC. CD8⁺ T cells are key mediators of antitumor immunity and are associated with IO benefit. We developed an artificial intelligence (AI)–based pipeline (VIGOR-CD8) that predicts spatial CD8⁺ immune signatures from routine baseline H&E whole-slide images using histopathology foundation model embeddings (H-Optimus-0) and virtual gene expression modeling (HE2Gene), and evaluated its ability to identify pts who do and do not derive IO benefit over Ch in CM227. Methods: 1,598 pts with advanced NSCLC were analyzed, including multi-institutional retrospective cohorts (n = 487; 65 for patch-level CD8⁺ prediction and overall survival (OS), 422 for patient-level OS) and a blinded CM227 validation subset (n = 1,111). For orthogonal validation, 86,470 H&E patches were co-registered with quantitative CD8⁺ immunofluorescence. H-Optimus-0 and HE2Gene immune-related embeddings were used to train a random forest classifier to predict patch-level CD8⁺ probability. Patch-level probabilities were aggregated into a patient-level CD8⁺ signature and dichotomized into biomarker-positive (B⁺) and biomarker-negative (B⁻) groups by the training-set median. Cox models assessed the impact of VIGOR-CD8 on OS. In CM227, prognostic and predictive utility were evaluated using treatment-specific analyses; investigators were blinded to outcomes, and models were trained on independent, non-overlapping cohorts. Results: VIGOR-CD8 was associated with longer OS in the testing cohort (n = 422; HR 0.68, 95% CI 0.53–0.87, p = 0.00163) and CM227 (n = 1,111; HR 0.8, 95% CI 0.67–0.96, p = 0.016), irrespective of treatment type and PD-L1 expression. Among pts with evaluable PD-L1, B⁺ pts treated with nivo+ipi had superior OS versus Ch (n = 617; HR 0.72, 95% CI 0.58–0.90, p = 0.003), while in B⁻ pts there was no significant OS difference between treatment arms (n = 130; HR 1.18, 95% CI 0.79–1.75, p = 0.436), supporting a predictive rather than purely prognostic role for VIGOR-CD8. Conclusions: An AI-derived CD8⁺ immune signature from routine baseline H&E slides was associated with favorable OS in CM227 and predicted differential benefit from nivo+ipi versus Ch. VIGOR-CD8 may help identify advanced NSCLC pts most likely to benefit from first-line dual IO, but further validation in independent and prospective trials is warranted.
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Sater, Sam, Bifulco, Carlo B, Rodriguez-Canales, Jaime, Yeong, Joe, Akturk, Guray, Angelo, Michael, Ballesteros-Merino, Carmen, Bankhead, Peter, Basu, Subham, Blando, Jorge M, Brajkovic, Saska, Cassano, Marco, Chen, Benjamin J , Coskun, Ahmet F, Cottrell, Tricia R, Andrea, Carlos E De, Edwards, Robin H, Engle, Logan L , Fan, Rong , Feldman, Michael, Fox, Bernard A. , Galon, Jerome, Gartrell, Robyn, Gnjatic, Sacha, Green, Benjamin F, Hellebust, Anne, Hewitt, Stephen, Hollmann, Travis J, Horn, Lucas A , Howat, William J, Hoyt, Clifford C, Jensen, Shawn M, Kulasinghe, Arutha, Lassoued, Wiem , Lott, Steven, Mansfield, James, Marwitz, Sebastian , Netto, George, Page, David B. , Parra, Edwin, Rodig, Scott J, Salgado, Roberto, Schapiro, Denis, Schalper, Kurt A , Sunshine, Joel C , Surace, Michael J, Szalay, Alexander S, Thurin, Magdalena, Villasboas, Jose C, Wharton, Keith, Wistuba, Ignacio I, Yearley, Jennifer H, Yuan, Yinyin, Zaki, Geroge, Ziai, James, Gnjatic, Sacha , Netto, George J. , Egelston, Colt , Engle, Logan L , Ernstoff, Marc S. , Fan, Rong , Fox, Bernard A , Gulley, James L , Horn, Lucas A , Lassoued, Wiem , Marwitz, Sebastian , Page, David B , Rimm, David , Schalper, Kurt A , Sunshine, Joel C , Taube, Janis M , Gnjatic, Sacha , Sater, Sam, Bifulco, Carlo B, Rodriguez-Canales, Jaime, Yeong, Joe Poh-Sheng , Akturk, Guray, Angelo, Michael, Ballesteros-Merino, Carmen, Bankhead, Peter, Basu, Subham, Blando, Jorge M, Brajkovic, Saška, Cassano, Marco , Chen, Benjamin J , Coskun, Ahmet F, Cottrell, Tricia R, Andrea, Carlos E De, Edwards, Robin H, Feldman, Michael, Galon, Jérôme , Gartrell, Robyn, Green, Benjamin F, Hellebust, Anne, Hewitt, Stephen, Hollmann, Travis J, Howat, William J, Hoyt, Clifford C, Jensen, Shawn M, Kulasinghe, Arutha, Lott, Steven, Mansfield, James, Parra, Edwin, Rodig, Scott J, Salgado, Roberto, Schapiro, Denis , Surace, Michael J, Szalay, Alexander S. , Thurin, Magdalena, Villasboas, Jose C, Wharton, Keith, Wistuba, Ignacio I. , Yearley, Jennifer H, Yuan, Yinyin, Zaki, Geroge, Ziai, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | December 21, 2025 | Volume: 13 | Issue: 12 | Pages: e012280

10.1136/jitc-2025-012280 | PMID 41423269 Get It

Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.
Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial
Rimm, DL, Holmes, Eileen , Schalper, KA, Bradbury, I, Zarrella, Elizabeth, Ellis, Catherine , Baselga, José , Eidtmann, Holger, Piccart, Martine , Harbeck, N., Perez, Edith A. , Pusztai, Lajos

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 24_Supplement | Pages: P1-08-09-P1-08-09

10.1158/0008-5472.sabcs13-p1-08-09 Get It

Abstract Background: Epidermal Growth Factor Receptor (EGFR, HER1) is known to heterodimerize with HER2 and may modulate the effectiveness of trastuzumab or lapatinib. Historically, it has been difficult to measure, but recently we reported a new, standardized, quantitative immunofluorescence assay and a novel EGFR antibody which showed that high levels of EGFR were associated with decreased benefit in the concurrent arm of the North Central Cancer Treatment Group (NCCTG/Alliance) N9831 trial (Rimm et al, SABCS 2012). Here we assess its value in the neo-adjuvant setting in the NeoALTTO trial. Methods: NeoALTTO randomized 455 breast cancer patients to neoadjuvant trastuzumab, lapatinib or both and showed benefit in both single anti-HER2 therapy arms, and the combination therapy showing about twice as much benefit as either single drug arm. We used the previously described AQUA method of quantitative immunofluorescence to measure EGFR levels using the D38B1 antibody on between 4 and 140 fields of view per slide on 353 specimens. The averaged EGFR score was standardized to the absolute concentration using cell lines and western blots and the 13 ng/ug total protein established in the N9831 trial was tested to determine predictive value for pathological complete response (pCR) defined as ypT0/is. Results: In NeoALTTO, 19% of the patients had EGFR levels above 13 ng/ug, compared to 16% in NCCTG N9831. The pCR rate was 35.3% in the patients with low EGFR, compared with 29.8% for high EGFR but this difference was not statistically significant. However, when adjusted for treatment and hormone receptor (HR) status, high EGFR is statistically significantly associated with lower response rate(p = 0.038). Continuous analysis measures were not significant. The effect on overall response at 6 weeks was also weakly significant when adjusting for treatment and HR status (p = 0.06). Surprisingly, for HR negative patients in the lapatinib only arm, the pCR rate in the low EGFR group was 47.2% compared with 16.0% in the high group. While this difference is statistically significant (p = 0.014), it should be interpreted cautiously because of the small numbers of patients and the multiple tests performed. Conclusions: High expression of EGFR by the AQUA platform appears to be associated with decreased pCR rate from HER2 targeted therapy in the neoadjuvant setting. This observation is consistent with NCCTG N9831. Although underpowered, high EGFR levels predicted decreased pCR rate from lapatinib, the opposite of that anticipated for this small molecule dual EGFR/HER2 inhibitor. Further studies are required to determine the clinical utility of this assay and the biological mechanisms underlying these observations. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P1-08-09.